Imquest Biosciences

Frederick, MD 21704

SBIR Award Summary

Total Number of Awards 9
Total Value of Awards $3.63MM
First Award Date 08/15/05
Most Recent Award Date 06/01/11

Key Personnel

Last Name Name Awards Contact
Buckheit Robert Walter Buckheit 7
Ham Anthony Sang Won Ham 1
Parsley Todd Bernard Parsley 1

9 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-09-080
Budget: 06/01/11 - 05/31/12

DESCRIPTION (provided by applicant): Although IQP-0410 possesses a favorable pharmacokinetic, safety pharmacology and toxicity profile, we believe that additional enhancement of biological activity is possible through additional development activities with lead molecules defined as the most active reverse transcriptase and virus entry inhibitors...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-09-080
Budget: 06/15/10 - 05/31/11

DESCRIPTION (provided by applicant): Highly active antiretroviral therapy (HAART) has been successfully utilized in HIV-infected individuals to significantly reduce disease progression and improve the prognosis of infected individuals. However, the side-effects, toxicity, and drug-drug interactions of HAART therapies have resulted in reduced pat...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-09-080
Budget: 06/01/10 - 05/31/11

DESCRIPTION (provided by applicant): Although IQP-0410 possesses a favorable pharmacokinetic, safety pharmacology and toxicity profile, we believe that additional enhancement of biological activity is possible through additional development activities with lead molecules defined as the most active reverse transcriptase and virus entry inhibitors...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-08-050
Budget: 09/05/09 - 08/31/10

DESCRIPTION (provided by applicant): Although the currently approved NNRTIs (nevirapine, delavirdine, efavirenz, etrivirine) are highly potent, significant improvements in therapeutic utility are still required. A new generation of NNRTIS must be developed which will allow once per day dosing, exhibit significantly reduced toxicity, be amenable ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-134
Budget: 02/06/09 - 01/31/10

DESCRIPTION (provided by applicant): The goals this Phase I SBIR grant are focused on the development of PG 301029 and chemically related compounds as therapeutics for treatment of hepatitis C virus infection. PG 301029 is a small molecule inhibitor of hepatitis C virus (HCV) replication that has been shown to be less toxic and have a larger the...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-20
Budget: 09/01/08 - 08/31/09

DESCRIPTION (provided by applicant): The goals of this Phase II research proposal focus on the further development of a topical microbicide for vaginal and rectal use from a small group of highly potent pyrimidinedione molecules identified in our Phase I research. Topical microbicides represent an important strategy for preventing the sexual tr...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-34
Budget: 06/03/08 - 05/31/09

DESCRIPTION (provided by applicant): The goal of this project is to define the mechanism of anti-HIV activity of the small molecule pyrimidinedione HIV inhibitor IQP-0410. IQP-0410 inhibits HIV replication by two distinct mechanisms, acting as a nonnucleoside reverse transcriptase inhibitor while also potently suppressing virus entry. Unlike oth...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-20
Budget: 09/01/07 - 08/31/08

DESCRIPTION (provided by applicant): The goals of this Phase II research proposal focus on the further development of a topical microbicide for vaginal and rectal use from a small group of highly potent pyrimidinedione molecules identified in our Phase I research. Topical microbicides represent an important strategy for preventing the sexual tr...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/15/05 - 02/28/06

DESCRIPTION (provided by applicant): This proposal is specifically designed to define a lead vaginal topical microbicide compound from a series of 78 pyrimidinedione molecules synthesized by the Samjin Pharmaceutical Co., Ltd. Topical microbicides represent an important strategy for preventing the transmission of HIV through sexual intercourse,...